| AZETUKALNER |
AZETUKALNER |
92%
|
Less: Direct external research and development costs: Azetukalner 47,073 31,501 |
| NEUROCRINE-BIOSCIENCES |
NEUROCRINE-BIOSCIENCES |
92%
|
In December 2019, as amended in January 2021 and February 2022, we entered into a license and collaboration agreement, or the Collaboration Agreement, with Neurocrine Biosciences to establish a colla… |
| 1ST-ORDER-PHARMACEUTICALS-INC |
1ST-ORDER-PHARMACEUTICALS-INC |
90%
|
In April 2017, we entered into an asset purchase agreement with 1st Order Pharmaceuticals, Inc., or 1st Order, pursuant to which we acquired all rights with respect to azetukalner |
| JEFFERIES-LLC |
JEFFERIES-LLC |
90%
|
The information set forth below in Item 8.01 of this report with respect to the pre-funded warrants issued and sold in the offering (described below) is incorporated by reference into this Item 1.01. |
| J-P-MORGAN-SECURITIES-LLC |
J-P-MORGAN-SECURITIES-LLC |
90%
|
The information set forth below in Item 8.01 of this report with respect to the pre-funded warrants issued and sold in the offering (described below) is incorporated by reference into this Item 1.01. |
| RBC-CAPITAL-MARKETS-LLC |
RBC-CAPITAL-MARKETS-LLC |
90%
|
The information set forth below in Item 8.01 of this report with respect to the pre-funded warrants issued and sold in the offering (described below) is incorporated by reference into this Item 1.01. |
| STIFEL-NICOLAUS-COMPANY-INCORPORATED |
STIFEL-NICOLAUS-COMPANY-INCORPORATED |
90%
|
The information set forth below in Item 8.01 of this report with respect to the pre-funded warrants issued and sold in the offering (described below) is incorporated by reference into this Item 1.01. |
| TD-SECURITIES-USA-LLC |
TD-SECURITIES-USA-LLC |
90%
|
The information set forth below in Item 8.01 of this report with respect to the pre-funded warrants issued and sold in the offering (described below) is incorporated by reference into this Item 1.01. |
| WILLIAM-BLAIR-COMPANY-L-L-C |
WILLIAM-BLAIR-COMPANY-L-L-C |
90%
|
The information set forth below in Item 8.01 of this report with respect to the pre-funded warrants issued and sold in the offering (described below) is incorporated by reference into this Item 1.01. |
| BAUSCH-HEALTH-COMPANIES-INC |
BAUSCH-HEALTH-COMPANIES-INC |
85%
|
1st Order previously acquired 1OP2198 from Valeant Pharmaceuticals Luxembourg S.a.r.l., an indirect subsidiary of Bausch Health Companies Inc. |
| ANRO |
Alto Neuroscience, Inc. |
72%
|
velopment and marketing efforts of our collaborators. • Our reliance on third parties to manufacture our product candidates may increase the risk that we will not have sufficient quantities of our pr… |
| ANRO |
Alto Neuroscience, Inc. |
72%
|
Reciprocal relationship from ANRO graph: Reciprocal relationship from XENE graph: velopment and marketing efforts of our collaborators. • Our reliance on third parties to manufacture our product cand… |
| AXSM |
Axsome Therapeutics, Inc. |
72%
|
velopment and marketing efforts of our collaborators. • Our reliance on third parties to manufacture our product candidates may increase the risk that we will not have sufficient quantities of our pr… |
| AXSM |
Axsome Therapeutics, Inc. |
72%
|
Reciprocal relationship from AXSM graph: Reciprocal relationship from XENE graph: velopment and marketing efforts of our collaborators. • Our reliance on third parties to manufacture our product cand… |
| BHC |
Bausch Health Companies Inc. |
72%
|
velopment and marketing efforts of our collaborators. • Our reliance on third parties to manufacture our product candidates may increase the risk that we will not have sufficient quantities of our pr… |
| BHC |
Bausch Health Companies Inc. |
72%
|
Reciprocal relationship from BHC graph: Reciprocal relationship from XENE graph: Reciprocal relationship from BHC graph: Reciprocal relationship from XENE graph: velopment and marketing efforts of ou… |
| NBIX |
Neurocrine Biosciences, Inc. |
72%
|
velopment and marketing efforts of our collaborators. • Our reliance on third parties to manufacture our product candidates may increase the risk that we will not have sufficient quantities of our pr… |
| NBIX |
Neurocrine Biosciences, Inc. |
72%
|
Reciprocal relationship from NBIX graph: Reciprocal relationship from XENE graph: Reciprocal relationship from NBIX graph: Reciprocal relationship from XENE graph: Reciprocal relationship from NBIX g… |
| NMRA |
Neumora Therapeutics, Inc. |
72%
|
velopment and marketing efforts of our collaborators. • Our reliance on third parties to manufacture our product candidates may increase the risk that we will not have sufficient quantities of our pr… |
| NMRA |
Neumora Therapeutics, Inc. |
72%
|
Reciprocal relationship from NMRA graph: Reciprocal relationship from XENE graph: Reciprocal relationship from NMRA graph: Reciprocal relationship from XENE graph: velopment and marketing efforts of … |
| ORANY |
ORANY |
72%
|
of inventory through measures such as cages, surveillance cameras and inventory reconciliations. Records must be maintained for the handling of all controlled substances, and periodic reports made to… |
| ORANY |
ORANY |
72%
|
Reciprocal relationship from ORANY graph: Reciprocal relationship from XENE graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from XENE graph: of inventory through measures suc… |
| PRAX |
Praxis Precision Medicines, Inc. |
72%
|
velopment and marketing efforts of our collaborators. • Our reliance on third parties to manufacture our product candidates may increase the risk that we will not have sufficient quantities of our pr… |
| PRAX |
Praxis Precision Medicines, Inc. |
72%
|
Reciprocal relationship from PRAX graph: Reciprocal relationship from XENE graph: velopment and marketing efforts of our collaborators. • Our reliance on third parties to manufacture our product cand… |
| RAPP |
Rapport Therapeutics, Inc. |
72%
|
Reciprocal relationship from RAPP graph: Reciprocal relationship from XENE graph: velopment and marketing efforts of our collaborators. • Our reliance on third parties to manufacture our product cand… |
| RAPP |
Rapport Therapeutics, Inc. |
72%
|
velopment and marketing efforts of our collaborators. • Our reliance on third parties to manufacture our product candidates may increase the risk that we will not have sufficient quantities of our pr… |
| SUPN |
Supernus Pharmaceuticals, Inc. |
72%
|
velopment and marketing efforts of our collaborators. • Our reliance on third parties to manufacture our product candidates may increase the risk that we will not have sufficient quantities of our pr… |
| SUPN |
Supernus Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from SUPN graph: Reciprocal relationship from XENE graph: Reciprocal relationship from SUPN graph: Reciprocal relationship from XENE graph: Reciprocal relationship from SUPN g… |
